IDEAYA Biosciences Provides a Business Update and Outlines 2026 Corporate Objectives at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
IDEAYA Biosciences Provides a Business Update and Outlines 2026 Corporate Objectives at the 44th Annual J.P. Morgan Healthcare Conference
IDEAYA Biosciences (NASDAQ:IDYA) is now covered by analysts at UBS Group AG. They set a "buy" rating and a $50.00 price target on the stock.
IDEAYA Biosciences (NASDAQ:IDYA) was given a new $60.00 price target on by analysts at Truist Financial Corporation.
IDEAYA Biosciences Announces Participation at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]